← Leaderboards
John A Berglund
University Of Oregon
$5,035,312
Attributed
$8,799,236
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,294,012 · 7
By mechanism
R01$8,500,281 · 5
P50$1,793,731 · 2
Top collaborators
- Masayuki Nakamori9 shared
- Kaalak Reddy9 shared
- Damian Seung-Ho Shin6 shared
- Hannah Shorrock6 shared
- Eric T Wang6 shared
- Robert C Spitale5 shared
- Maurice S Swanson5 shared
- Nicholas Elwood Johnson1 shared
Most similar at University Of Oregon
Same institution · by research overlap
- Hironori Uehara$409,750
- Micah J Bodner$13,163
Others in their field
Top investigators on “Myotonic Dystrophy”
- Charles A Thornton · Virginia Commonwealth University$24,947,271
- Laura Pw Ranum · University Of Minnesota Twin Cities$17,009,224
- Thomas Alexander Cooper · Baylor College Of Medicine$16,038,073
- Maurice S Swanson · University Of California, San Diego$15,936,599
- Richard T Moxley · University Of Rochester$12,413,577
- Lubov T Timchenko · Cincinnati Childrens Hosp Med Ctr$11,748,709
Research focus
Myotonic DystrophyRna SplicingProteinsLeadRna-Binding ProteinsTranscriptMyotoniaMolecularEventAlternative SplicingMuscular DystrophiesSmall MoleculeCell ModelGenesGain Of FunctionDesignMouse ModelRegulationCell PhysiologyIn VivoSymptomsMrna PrecursorSmall Molecule TherapeuticsComplex
Grant awards (35)
Preparing for Therapeutics across the Spectrum of Myotonic Dystrophy$1,494,776
P50 · FY2025 · AR
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias$573,747
R01 · FY2025 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$425,205
R01 · FY2025 · NS · contact PI
Shared Resource Core$298,955
P50 · FY2025 · AR · contact PI
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias$79,387
R01 · FY2025 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$69,192
R01 · FY2025 · NS · contact PI
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias$27,362
R01 · FY2025 · NS · contact PI
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias$640,327
R01 · FY2024 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$465,688
R01 · FY2024 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$69,192
R01 · FY2024 · NS · contact PI
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias$32,057
R01 · FY2024 · NS · contact PI
Alternative Splicing and Development of Small Molecule Therapeutics in CAG Expansion Spinocerebellar Ataxias$24,542
R01 · FY2024 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$13,694
R01 · FY2024 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$488,445
R01 · FY2023 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$55,928
R01 · FY2023 · NS · contact PI
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy$45,776
R01 · FY2023 · NS · contact PI
Design, synthesis and efficacy of new small molecule therapeutics to impede myotonic dystrophy$509,840
R01 · FY2022 · NS · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$414,445
R01 · FY2020 · GM · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$446,800
R01 · FY2019 · GM · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$407,973
R01 · FY2018 · GM · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$250,000
R01 · FY2018 · GM · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$32,354
R01 · FY2018 · GM · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$421,098
R01 · FY2017 · GM · contact PI
Targeting a Toxic RNA with Small Molecules$356,171
R01 · FY2014 · AR · contact PI
Targeting a Toxic RNA with Small Molecules$345,503
R01 · FY2013 · AR · contact PI
Targeting a Toxic RNA with Small Molecules$363,909
R01 · FY2012 · AR · contact PI
Targeting a Toxic RNA with Small Molecules$22,374
R01 · FY2012 · AR · contact PI
Targeting a Toxic RNA with Small Molecules$315,571
R01 · FY2011 · AR · contact PI
Targeting a Toxic RNA with Small Molecules$310,240
R01 · FY2010 · AR · contact PI
Molecular Mechanisms of Myotonic Dystrophy$239,159
R01 · FY2010 · AR · contact PI
Molecular Mechanisms of Myotonic Dystrophy$241,915
R01 · FY2009 · AR · contact PI
Molecular Mechanisms of Myotonic Dystrophy$66,765
R01 · FY2009 · AR · contact PI
Molecular Mechanisms of Myotonic Dystrophy$242,359
R01 · FY2008 · AR · contact PI
Molecular Mechanisms of Myotonic Dystrophy$247,728
R01 · FY2007 · AR · contact PI
Molecular Mechanisms of Myotonic Dystrophy$255,535
R01 · FY2006 · AR · contact PI